SEARCH

SEARCH BY CITATION

References

  • 1
    Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene 1999; 18: 53408.
  • 2
    Anderson J, Gordon A, Pritchard-Jones K, Shipley J. Genes, chromosomes and Rhabdomyosarcoma. Genes Chromosomes Cancer 1999; 26: 27585.
  • 3
    Dagher R, Helman L. Rhabdomyosarcoma: an overview. The Oncologist 1999; 4: 3444.
  • 4
    Epstein JA, Shapiro DN, Cheng J, Lam PYP, Maas RL. PAX3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA 1996; 93: 421318.
  • 5
    Epstein JA, Song B, Lakkis M, Wang C. Tumor-specific PAX3-FKHR trascription factor, but not Pax3, activates platelet-derived growth factor alpha receptor. Mol Cell Biol 1998; 18: 411830.
  • 6
    Aylon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001; 11: 28997.
  • 7
    Libura J, Drukala J, Majka M, Tomescu O, Navenot OT, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, Ratajczak MZ. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis and adhesion. Blood 2002; 100: 25972606.
  • 8
    Tomescu O, Shujuan JX, Stezlecki D, Bennicelli JL, Ginsberg J, Pawel B, Barr FG. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3 and PAX7 expressio. Lab Invest 2004; 84: 106070.
  • 9
    Anderson J, Gordon T, McManus A, Mapp T, Gould S, Kelsey A, McDowell H, Pinkerton R, Shipley J, Pritchard-Jones K. Detection of the PAX3-FKHR fusion gene in paedriatic Rhabdomyosarcoma: a reproducible predictor of outcome? Br J Cancer 2001; 85: 83135.
  • 10
    Anderson MJ, Shelton GD, Cavenee WK, Arden KC. Embryonic expression of the tumor associated PAX3-FKHR fusion protein interferes with the developmental functions of PAX3. Proc Natl Acad Sci USA 2001; 98: 158994.
  • 11
    Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002; 20: 26729.
  • 12
    Liu ET. Classification of cancers by expression profiling. Curr Opin Genet Dev 2003; 13: 97103.
  • 13
    Greer BT, Khan J. Diagnostic classification of cancer using DNA microarrays and artificial intelligence. Ann NY Acad Sci 2004; 1020: 4966.
  • 14
    Raetz EA, Moos PJ. Impact of microarray technology in clinical oncology. Cancer Invest 2004; 22: 31220.
  • 15
    Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM, Meltzer PS. Gene expression profiling of alveolar Rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998; 58: 500913.
  • 16
    Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS. cDNA microarrays detect activation of myogenic trascription program by the PAX3-FKHR fusion oncogene. Prot Natl Acad Sci USA 1999; 96: 132649.
  • 17
    Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, Buhlmann P, Niggli FK, Schafer BW. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004; 64: 553945.
  • 18
    Schaaf G, Ruijter JM, van Ruissen F, Zwijnenburg DA, Waaijer R, Valentijn LJ, Benit-Deekman J, van Kampen AHC, Baas F, Kool M. Full transcriptome analysis of Rhabdomyosarcoma, normal and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB Journal 2005; 19: 4046.
  • 19
    Baer C, Nees M, Breit S, Selle B, Kulozik AE, Schaefer KL, Braun Y, Wai D, Poremba C. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004; 110: 68794.
  • 20
    Basso D, Millino C, Greco E, Romualdi C, Fogar P, Valerio A, Bellin M, Zambon CF, Navaglia F, Dussini N, Ayogaro A, Pedrazzoli S et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut 2004; 53: 115966.
  • 21
    De Pitta C, Tombolan L, Campo Dell'Orto M, Accordi B, te Kronnie G, Romualdi C, Vitulo N, Basso G, Lanfranchi G. A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica 2005; 90: 8908.
  • 22
    Simon R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005; 97: 8667.
  • 23
    Furlanello C, Serafini M, Merler, Jurman G. Semi-supervised learning for molecular profiling. IEEE Transactions on Computational Biology and Bioinformatics 2005; 2: 11018.
  • 24
    Frascella E, Rosolen A. Detection of the MyoD1 trascript in rhabdomyosarcoma cell lines and tumor samples by riverse trascription polymerase chain reaction. Am J Pathol 1998; 152: 57783.
  • 25
    Frascella E, Toffolatti L, Rosolen A. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet 1998; 102: 1049.
  • 26
    Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, Heyn R, Lawrence W, Newton W, Ortega J. The intergroup Rhabdomyosarcoma study-I. Cancer 1998; 61: 20920.
  • 27
    Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 3748.
  • 28
    Tusher VG, Tibshirani R, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2001; 98: 511621.
  • 29
    Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 656772.
  • 30
    Dysvik B, Jonassen I. J-Express: exploring gene expression data using Java. Bioinformatics 2001; 17: 36970.
  • 31
    Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 48892.
  • 32
    Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the analysis of DNA microarray data: class prediction methods. J Natl Cancer Inst 2003; 95: 1418.
  • 33
    Furlanello C, Serafini M, Merler S, Jurman G. Entropy-Based Gene Ranking without Selection Bias for the Predictive Classification of Microarray Data. BMC Bioinformatics 2003; 4: 54.
  • 34
    Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res 2001; 29: e45.
  • 35
    Campanaro S, Romualdi C, Fanin M, Celegato B, Pacchioni B, Trevisan S, Laveder P, De Pitta C, Pegoraro E, Hayashi YK, Valle G, Angelini C Lanfranchi G. Gene expression profiling in dysferlinophaties using a dedicated muscle microarray. Hum Mol Genet 2002; 11: 328398.
  • 36
    Lanfranchi G, Muraro T, Caldara F, Pacchioni B, Pallavicini A, Pandolfo D, Toppo S, Trevisan S, Scarso S Valle G. Identification of 4370 expressed sequence tags from a 3′-end-specific cDNA library of human skeletal muscle by DNA sequencing and filter hybridization. Genome Res 1996; 6: 3542.
  • 37
    Laveder P, De Pittà C, Toppo S, Valle G, Lanfranchi G. A two-step strategy for constructing specifically self-subtracted cDNA libraries. Nucleic Acids Res 2002; 30: e38.
  • 38
    Staal FJ, van der Burg M, Wessels LF, Barendregt BH, Baert MR, van den Burg CM, van Huffel C, Langerak AW, van der Velden VH, Reinders MJ, van Dongen JJ. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 2003; 17: 132432.
  • 39
    Grundy R, Anderson J, Gaze M, Gerrard M, Glaser A, Gordon A, Malone M, Pritchard-Jones K, Michalski A. Congenital alveolar rhabdomyosarcoma: clinical and molecular distinction from alveolar rhabdomyosarcoma in older children. Cancer 2001; 91: 60612.
  • 40
    Joshi D, Anderson JM, Padais C, Breneman J, Parham DM, Crist W. Age is indipendent prognostic factor in rhabdomyosarcoma: a report from the tissue sarcoma committee of the children's oncology group. Pediatr Blood Cancer 2004; 42: 6473.
  • 41
    Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091102.
  • 42
    Liu FT. Galectins: a new family of regulators of inflammation. Clin Immunol 2000; 97: 7988.
  • 43
    Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 1997; 185: 18518.
  • 44
    Watt DJ, Jones GE, Goldring K. The involvement of galectin-1 in skeletal muscle determination, differentiation and regeneration. Glycoconj J 2004; 19: 61519.
  • 45
    Wechsler-Reya RJ, Elliott KJ, Prendergast CG. A role for the putative tumor suppressor Bin1 in muscle cell differentiation. Mol Cell Biol 1998; 18: 56675.
  • 46
    Lee E, Marcucci M, Daniell L, Pypaert M, Weisz OA, Ochoa GC, Farsad K, Wenk MR, De Camilli P. Amphiphysin 2 (Bin1) and T-Tubule biogenesis in muscle. Science 2002; 297: 11936.
  • 47
    DuHadaway JB, Sakamuro D, Ewert DL, Prendergast GC. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res 2001; 61: 31516.
  • 48
    Gurumurthy S, Vasudevan KM, Rangnekar VM. Regulation of apoptosis in prostate cancer. Cancer and Metastasis Rev 2001; 20: 22543.
  • 49
    Zhao ZS, Manser E, Loo TH, Lim L. Coupling of PAK interacting exchange factor PIX to GIT1 promotes focal complex disassembly. Mol Cell Biol 2000; 20: 635463.
  • 50
    Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 1999; 147: 100922.
  • 51
    Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1999; 1: 25359.
  • 52
    Stanyon CA, Bernard O. LIM-kinase1. Int J Biochem Cell Biol 1999; 31: 3894.
  • 53
    Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem 1995; 270: 239346.
  • 54
    Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995; 81: 1147157.
  • 55
    Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997; 11: 46375.
  • 56
    Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG. Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. J Biol Chem 1999; 274: 252459.
  • 57
    Charrasse S, Causeret M, Comunale F, Bonet-Kerrache A, Gauthier-Rouviere C. Rho GTPases and cadherin-based cell adhesion in skeletal muscle development. J Muscle Res Cell Motil 2003; 24: 30913.
  • 58
    Heller H, Gredinger E, Bengal E. Rac1 inhibits myogenic differentiation by preventing the complete withdrawal of myoblasts from the cell cycle. J Biol Chem 2001; 276: 3730716.
  • 59
    Kanety H, Madajar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldowa B, Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993; 77: 22933.
  • 60
    Boulle N, Baudin E, Gicquel C, Logie A, Bertherat J, Penfornis A, Bertagna X, Luton JP, Schlumberger M, Le Bouc Y. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. Eur J Endocrinol 2001; 144: 2936.
  • 61
    Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L, Zhou YH, Liao WS, Fuller GN, Zhang W. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 2003; 63: 431521.
  • 62
    Yang CQ, Zhan X, Hu X, Kondepudi A, Perdue JF. The expression and characterisation of human recombinant proinsulin-like growth factor-2 precursor. Endocrinology 1996; 137: 276673.
  • 63
    Minniti CP, Tsokos M, Newton WA,Jr, Helman LJ. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 1994; 101: 198203.
  • 64
    Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986; 44: 5178.
  • 65
    Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 85968.
  • 66
    Kuo W, Jenssen T, Butte A, Oho-Machado L, Kohane I. Analysis of mRNA measurements from two different microarray technologies. Bioinformatics 2002; 18: 40512.
  • 67
    Tan P, Downey T, Spitznagel EJ, Xu P, Fu D, Dimitrov D, Lempicki R, Raaka B, Cam M. Evaluation of gene expression measurements from commercial platforms. Nucleic Acids Res 2003; 31: 567684.
  • 68
    Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995; 270: 4847.